Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease?
Launched by UNIVERSITY OF ULSTER · Aug 28, 2007
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Twenty patients with moderate to severe bronchiectasis admitted to hospital with an acute exacerbation were recruited (October 2004 to April 2006) and allocated to one of two groups that received twice daily airway clearance treatment for a course of IVAB. Group 1 {ACBT} and group 2 {NIV and ACBT}. A number of measurements were recorded on the first and final day of treatment as well as daily to provide important comparative information on physiological changes, ease of use, and clinical efficacy.
Outcomes measured on day 1 and final day of IVAB were: LifeshirtTM which recorded tidal volum...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Moderate to severe bronchiectasis (FEV1 \< 60%),
- • Indicators of difficulty expectorating sputum, and
- • An acute exacerbation requiring intravenous antibiotics (IVAB)
- Exclusion Criteria:
- • Unable to tolerate positive pressure
- • Presence of pneumothorax
About University Of Ulster
The University of Ulster is a leading academic institution dedicated to advancing knowledge and innovation through research and education. Renowned for its commitment to excellence, the university actively engages in clinical trials aimed at improving healthcare outcomes and addressing pressing health challenges. With a robust infrastructure for research and a multidisciplinary approach, the University of Ulster fosters collaboration among researchers, healthcare professionals, and industry partners. Its focus on evidence-based practices ensures that clinical trials are designed and conducted to the highest ethical and scientific standards, contributing valuable insights to the field of medicine and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belfast, Northern Ireland, United Kingdom
Patients applied
Trial Officials
Prof Elborn, MD
Principal Investigator
Belfast City Hospital and Queens University Belfast
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials